Recro Pharma, Inc. (REPH) financial statements (2021 and earlier)

Company profile

Business Address 490 LAPP ROAD
MALVERN, PA 19355
State of Incorp. PA
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments193964642020
Cash and cash equivalents193961642020
Short-term investments  3   
Receivables1413101090
Inventory, net of allowances, customer advances and progress billings15111099 
Inventory15111099 
Prepaid expense    11
Contract with customer, asset95
Deferred costs    1 
Other undisclosed current assets3431  
Total current assets:607187853920
Noncurrent Assets
Operating lease, right-of-use asset0
Property, plant and equipment4246393738 
Intangible assets, net (including goodwill)839414446 
Goodwill46666 
Intangible assets, net (excluding goodwill)332353740 
Deferred costs     3
Deferred tax assets, net 191716 
Other undisclosed noncurrent assets     (3)
Total noncurrent assets:50849998100 
TOTAL ASSETS:11015518618313920
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities519181451
Accounts payable158421
Accrued liabilities414101031
Employee-related liabilities     0
Debt0  25 
Disposal group, including discontinued operation1     
Business combination, contingent consideration, liability 1032   
Other undisclosed current liabilities     (0)
Total current liabilities:629501691
Noncurrent Liabilities
Long-term debt and lease obligation11164542225 
Long-term debt, excluding current maturities11064542225 
Operating lease, liability0
Liabilities, other than long-term debt 8150   
Business combination, contingent consideration, liability 8150   
Other undisclosed noncurrent liabilities 147364 
Total noncurrent liabilities:1111461079589 
Total liabilities:117175157111981
Stockholders' equity
Stockholders' equity attributable to parent(7)(20)29724019
Common stock000000
Additional paid in capital2001691401337153
Accumulated other comprehensive loss  (0)   
Accumulated deficit(207)(188)(111)(61)(31)(34)
Total stockholders' equity:(7)(20)29724019
TOTAL LIABILITIES AND EQUITY:11015518618313920

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues9977726952 
Cost of revenue(53)(47)(46)(42)(32) 
Cost of goods and services sold(51)(43)(38)(37)(28) 
Gross profit:4631262820 
Operating expenses(22)(85)(66)(54)(27)(12)
Operating income (loss):24(54)(40)(26)(7)(12)
Nonoperating income (expense) 1000(4)
Investment income, nonoperating 10000
Interest and debt expense(20)(9)(12)(6)(6)(4)
Income (loss) from continuing operations before equity method investments, income taxes:4(62)(52)(31)(13)(20)
Other undisclosed income from continuing operations before income taxes20     
Income (loss) from continuing operations before income taxes:24(62)(52)(31)(13)(20)
Income tax expense (benefit)(1)(17)2116 
Income (loss) from continuing operations:23(80)(50)(30)3(20)
Loss from discontinued operations(23)     
Income (loss) before gain (loss) on sale of properties:(1)(80)(50)(30)3(20)
Other undisclosed net loss(18)     
Net income (loss):(19)(80)(50)(30)3(20)
Other undisclosed net income attributable to parent     4
Net income (loss) attributable to parent:(19)(80)(50)(30)3(16)
Preferred stock dividends and other adjustments     (1)
Net income (loss) available to common stockholders, basic:(19)(80)(50)(30)3(17)
Dilutive securities, effect on basic earnings per share    (1) 
Net income (loss) available to common stockholders, diluted:(19)(80)(50)(30)2(17)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss):(19)(80)(50)(30)3(20)
Other comprehensive income (loss) 0(0)   
Comprehensive income (loss), net of tax, attributable to parent:(19)(80)(50)(30)3(20)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: